Key Insights

Highlights

Treatment Research

2 treatments under study, led by Nanatinostat

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05011058Phase 2Terminated

An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

Showing all 1 trials

Research Network

Common Treatments

  • Nanatinostat1
  • Nanatinostat In Combination With Valganciclovir1

Active Sponsors

  • Viracta Therapeutics, Inc.1

Top Investigators

Related Conditions

  • Ebvrelated Ptld1
  • Ebvrelated Lymphoproliferative Disorder1
  • Epsteinbarr Virus Associated Lymphoma1
  • Epsteinbarr Viruspositive Ebv Relapsedrefractory Lymphomas1
  • Ebvpositive Dlbcl Nos1

Activity Timeline